---
title: "Skyrizi (risankizumab-rzaa) in plaque psoriasis: Specific populations questions"
description: "Specific populations questions on Skyrizi (risankizumab-rzaa) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pediatric use. Questions: Is Skyrizi approved for children with plaque psoriasis? How well does Skyrizi work in children aged 12 and older with plaque psoriasis? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/specific-populations"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Skyrizi (risankizumab-rzaa) in plaque psoriasis: Specific populations questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Skyrizi](https://www.skyrizihcp.com/prescribinginfo)

Specific populations questions that apply to every indication of Skyrizi are on [Skyrizi (risankizumab-rzaa), all indications: Specific populations](https://www.evicenter.com/medical-information/skyrizi/specific-populations).

## Pediatric use

<a id="skyrizi-children-approval"></a>

### Is Skyrizi approved for children with plaque psoriasis?

Applies to: Pediatric patients 6 years of age and older with moderate-to-severe plaque psoriasis

> “Moderate-to-Severe Plaque Psoriasis  
> The safety and effectiveness of SKYRIZI for the treatment of moderate-to-severe plaque 
> psoriasis have been established in pediatric patients 6 years of age and older who are candidates 
> for systemic therapy or phototherapy.  
> Use of SKYRIZI for this indication is supported by evidence from a four-part trial in a total of 
> 137 pediatric subjects 6 years of age and older with moderate-to-severe plaque psoriasis. In 
> addition to two lead-in pharmacokinetic cohorts, the trial also included a randomized, efficacy 
> assessor-blinded, active treatment-controlled cohort that enrolled 82 pediatric subjects 12 years 
> of age and older and a single-arm, open-label cohort that enrolled 30 pediatric subjects 6 to less 
> than 12 years of age [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical 
> Studies (14.1)].  
> The safety and effectiveness of SKYRIZI have not been established in pediatric patients younger 
> than 6 years of age with moderate-to-severe plaque psoriasis.”

Source: [SKYRIZI: Prescribing information, page 16, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=16)

<a id="skyrizi-children"></a>

### How well does Skyrizi work in children aged 12 and older with plaque psoriasis?

Applies to: Pediatric patients 6 years of age and older with moderate-to-severe plaque psoriasis

> “Subjects were randomized 2:1 to receive SKYRIZI (N = 54) or ustekinumab (N = 28). Subjects 
> weighing 40 kg or greater received SKYRIZI 150 mg and subjects weighing less than 40 kg 
> received SKYRIZI 55 mg at Week 0, Week 4, and every 12 weeks thereafter.”

Source: [SKYRIZI: Prescribing information, page 26, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=26)

> “The co-primary endpoints were sPGA score of 0 (“clear”) or 1 (“almost clear”) and at least a 2-
> point improvement from baseline, and PASI 75 at Week 16. The duration of treatment was up to 
> 68 weeks.”

Source: [SKYRIZI: Prescribing information, page 26, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=26)

> “Table 11. Efficacy Results at Week 16 in Pediatric Subjects 12 Years of Age and Older with 
> Moderate-to-Severe Plaque Psoriasis in PsO-6 
>
> SKYRIZI 
> (N = 54) 
> n (%) 
> sPGA 0 or 1 (“clear or almost clear”)<sup>a,b</sup> 
> 37 (69) 
> PASI 75<sup>a</sup>  
> 46 (85) 
> PASI 90  
> 35 (65) 
> PASI 100  
> 22 (41) 
> sPGA 0 (“clear”) 
> 22 (41) 
> <sup>a</sup>co-primary endpoints 
> <sup>b</sup>and at least a 2-point improvement from baseline at Week 16”

Source: [SKYRIZI: Prescribing information, page 26, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=26)

> “Subjects originally treated with SKYRIZI who achieved sPGA of 0 or 1 at Week 16 were re-
> randomized to continue SKYRIZI every 12 weeks through Week 52 or were withdrawn from 
> treatment. For subjects who were re-randomized and also had at least a 2-point improvement in 
> sPGA from baseline at Week 16, 95% (18/19) of the subjects continuing SKYRIZI had sPGA of 
> 0 or 1 and at least a 2-point improvement from baseline at Week 52 compared with 39% (7/18) 
> for those withdrawn from SKYRIZI.”

Source: [SKYRIZI: Prescribing information, page 26, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=26)

Note: Table 11 reports the SKYRIZI arm (N=54) only, as n (%); the label does not give the ustekinumab arm results.

## Related pages
- [Medical information: Skyrizi (risankizumab-rzaa): Plaque psoriasis](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/access-and-coverage)
